Why First-Time Leaders Are the Biggest Hidden Risk in Biotech Scale-Ups
In biotech scale-ups, talent risk rarely announces itself loudly. It does not arrive as incompetence, bad intent, or lack of intelligence. More often, it appears quietly—embedded in promotion decisions that feel logical, fair, and even inspiring at the time they are made.
One of the most underestimated risks is appointing first-time leaders into roles that sit at the fault line between science, regulation, capital, and operational delivery. This is not an argument against developing talent—it is an argument for recognising where development ends and organisational risk begins.
The Promotion Trap in High-Growth Biotech
Early success is driven by a small group of highly capable individuals—often scientists, clinicians, or technical experts who carry deep institutional knowledge. Promoting them internally offers continuity, loyalty, and speed. It avoids the perceived disruption of hiring “outsiders” who may not understand the science or culture. But what looks like stability can conceal fragility. Leadership at scale is not an extension of technical excellence. It is a fundamentally different discipline, requiring judgment under uncertainty and the willingness to make decisions that optimise the company rather than a single function.
Scale Changes the Job—Whether the Leader Changes or Not
The most dangerous assumption is that the role remains the same as the company grows. A Head of Function at 40 people is not doing the same job at 120, and at 250 it is entirely different. The skills that created early momentum—hands-on execution, deep subject matter ownership become liabilities if they are not replaced with delegation, systems thinking, and strategic judgment. First-time leaders are rarely told this explicitly. Instead, they are expected to “grow with the role” with no formal training, while the organisation quietly outpaces their development curve. By the time the gap becomes visible, the consequences are already embedded in the organisation.
First-Time Leaders Struggle—Quietly
First-time leaders rarely fail loudly, they often succeed just enough to delay detection. Common patterns include:
Over-reliance on personal expertise instead of building decision-capable teams
Difficulty challenging peers or managing upwards
Avoidance of conflict between cross-functional teams
Excessive detail orientation when strategic abstraction is required
Delayed escalation of risk due to uncertainty or fear of appearing incompetent
In regulated, capital-intensive environments, these behaviours do not immediately trigger alarms. Clinical timelines still progress. Regulatory submissions still move forward. Headcount grows. On the surface, everything appears functional. Even if things look okay at first, mistakes or gaps in leadership create hidden costs that only show up later—costs that can hurt projects, compliance, people, and growth.
Boards and CEOs Often Miss the Risk
This risk persists because it sits in an uncomfortable space:
Questioning internal promotions feels disloyal
Replacing a first-time leader can feel like personal failure
The outcomes of decisions often appear much later, making cause and effect difficult to isolate
Technical credibility is mistaken for leadership competence
Boards may lack direct scale-up pattern recognition in regulated, capital-intensive environments
In early-stage biotech, boards are often assembled for scientific credibility, investor representation, or commercial experience. Those attributes matter. But they do not automatically translate into an ability to assess leadership scalability. When few around the table have personally led through critical regulatory milestones, clinical setbacks, audit exposure, or rapid headcount expansion, the signals of leadership strain are easy to misinterpret. Leaders themselves are often unaware of the gap. Without prior exposure to scaled leadership, there is no internal reference point for what “good” looks like at the next level. As explored in my previous article, Avoiding Plato’s “Double Ignorance”: A Guide for Business Leaders, this reflects Plato’s concept of “double ignorance” — not simply lacking knowledge, but lacking awareness of that lack. In leadership transitions, that blind spot does not remain theoretical; it becomes embedded in governance, capital allocation, and execution risk.
